

About Recce Pharmaceuticals Ltd



Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is pioneering the development and commercialisation of a New Class of Synthetic **Anti-Effectives** designed to address the urgent global health threat posed by antibiotic-resistant superbugs and emerging viral pathogens.

- ✓ Proprietary new class of anti-infectives against bacteria and viruses
- ✓ Designed to work against antibiotic-resistant bacteria.
- ✓ Multiple Phase I and Phase II clinical programs, addressing unmet medical needs

- Amend to: Anti-Infectives

About Us



Home > Company > About Us

An Emerging Global Leader in the New Generation of Anti-Infective Therapies.

Recce Pharmaceuticals Ltd (**ASX: RCE**) are pioneering a new class of synthetic anti-infectives to address the urgent global health threat posed by superbugs and emerging viral pathogens

Origin of

- Amend to: (ASX:RCE, FSE:R9Q)

Recce (pronounced Re-Key) originates from the military term 'Reconnaissance' as a military tactic – 'the aggressive assessment of the disposition of the enemy'. In other words, get troops behind enemy lines, identify the enemy, eliminate the threat, and escape without being noticed.

We have adopted this approach to anti-infectives, where they are designed to:

- Enter the human body;
- Find the infection and threat (deadly bacteria and viruses);
- Eliminate the threat; and
- Exit without being noticed (side effects)

Dr Graham Melrose



Recce Pharmaceuticals was founded by Dr Graham Melrose, a former Executive Director and head of research at Johnson and Johnson Asia Pacific and Australia, building upon his early, independent research, Recce Pharmaceuticals was formed.

- Capitalise highlighted text to Head of Research at Johnson and Johnson Asia Pacific and Australia

Our Visions and Values

"To address the global health threat of antimicrobial with a revolutionary portfolio of synthetic infectives."



Discover

New synthetic polymer-based drugs uniquely designed for targeting major human health threats.



Patent

With over 40 granted patents and patent applications across four families, Recce is well positioned to continue expanding its wholly owned international patent.



Commercialise

As an Australian Stock Exchange (ASX:RCE) listed company, Recce Pharmaceuticals Ltd is well funded to pursue its drug development activities with a particular focus on

- Amend to: "To address the global health threat of antimicrobial resistance with a revolutionary portfolio of synthetic anti-infectives"

Commercial Strategy

We are committed to addressing the global health threat posed by antibiotic resistant superbugs and emerging viral pathogens through pioneering a New Class of Synthetic Anti-Infectives. Our approach to treating bacterial and viral infections has the potential to transform the current anti-infective business model.



Proprietary **new class of anti-infectives** against bacteria and viruses, protected by Composition of Matter Patent.

- Amend to: antibiotic-resistant



Multiple Phase I **AND** Phase II clinical programs, addressing the needs of the patients battling bacterial and viral infections.

- Lowercase: and

Board of Directors page

Home > Company > Board of Directors

Recce Pharmaceuticals includes a diverse management team of experts in clinical research and business development who are committed to addressing the urgent global health threat posed by **antibiotic resistant** superbugs and emerging viral pathogens.

Board of Directors



Dr John Prendergast

Executive Chairman
BSc (Hons), MSc (UNSW), PhD (UNSW), CSS (HU)



James Graham

Managing Director & Chief Executive Officer
B.Com. (Entrepreneurship), GAICD

- Hyphenate antibiotic-resistant



Dr Alan Dunton

Non-Executive Director

BSc (BioChem) Hons, M.D. (NYU)

US based, Director of Palatin Technologies. Over three decades of senior pharmaceutical experience incl. President and MD of Janssen Research Foundation (J&J Research). Dr Dunton has advanced a number of blockbuster antibiotics through regulatory review and commercialization at Fortune 500 companies including J&J and Roche.

- Use alan's updated photo (see attached on upwork)
- Amend Alan's bio to: US based, Director of Palatin Technologies. Over three decades of senior pharmaceutical experience incl. President and MD of Janssen Research Foundation (Johnson & Johnson). Dr Dunton has advanced a number of blockbuster antibiotics through regulatory review and commercialization at Fortune 500 companies including J&J and Roche.



Maggie Niewidok

Company Secretary

Maggie is an admitted lawyer and employee of Automic Group. Maggie is an experienced corporate lawyer and is the Company Secretary to various ASX Listed and unlisted companies, across a range of industries.

- Update maggie's bio to this: Maggie is an admitted lawyer and employee of Kardos Scanlan Corporate Lawyers. Maggie is an experienced corporate lawyer and is the Company Secretary to various ASX Listed and unlisted companies, across a range of industries.



Dr Philip Sutton

Vice President of Translational Sciences

BSc (Hons), PhD

Global infectious disease expert with over 30 years of research and industry experience, having served as former Head of Immunology at CSL Ltd in Melbourne. Chief Editor of textbook "Helicobacter pylori in the 21st Century" and has co-authored 92 manuscripts published in peer-reviewed journals.

- Remove Dr Philip Sutton from website

Intellectual Property

Recce Pharmaceuticals currently has four wholly owned patent families, which include over 30 patents or patent applications and are constantly expanding, broadening, and developing the intellectual property portfolio.

Recce is committed to protecting its intellectual property estate of patent rights and trade secrets as well as the potential commercial and/or clinical advantages this protection provides for its proprietary technology.

Recce's patent portfolio includes issued patents and patent applications in the world's major markets, including the United States, Europe, Japan, China and Australia.

Patent Families

Patent Family 1 – Granted

Protecting Recce's unique and highly economical manufacturing process.

Filed

 Australia

Expiry

2028

Status

Granted

- Update number to 40

Patent Family 3 – Provisional

Protecting Recce's anti-viral and anti-cancer applications.

Filed

 Australia

 USA

 Europe

 Germany

 Spain

 France

 UK

 Italy

 Sweden

 Japan

Expiry

2037

2037

2037

2037

2037

2037

2037

2037

2037

2037

Status

Pending

Granted

Granted

Granted

Granted

Granted

Granted

Granted

Granted

Granted

- Change to granted

Science > Pipeline


Asset and Route of administration	Indications
R327 Intravenous*	Serious/life threatening bacterial infections including sepsis
	Urinary tract infections including urosepsis
	Multidose, early stage sepsis efficacy study
R327 Topical*	Wound infections including infected burns
	Diabetic Foot Ulcers
RCE Compounds*	<i>Mycobacterium abscessus</i> pre-clinical program
	Bacterial Sinusitis pre-clinical program
	Additional TBA pre-clinical program

- Please match the pipeline wording below (ignore text colours)

Asset and Route of Administration	Indications
R327 Intravenous*	<p>Serious/life threatening bacterial infections including sepsis</p> <p>Urinary tract infections including urosepsis</p> <p>Multidose, early stage, rapid infusions sepsis efficacy study</p>
R327 Topical*	<p>Wound infections including infected burns</p> <p>Diabetic Foot Ulcer Infections</p>
Pre-Clinical Programs* <i>Various routes of administration</i>	<p><i>Mycobacterium abscessus</i></p> <p>Bacterial Sinusitis</p> <p>Additional TBA</p>

***Anti-bacterial program**

Mechanism of action page



A Multi-Layered Mechanism of Action

R327 activity against *Escherichia coli*

Without R327




R327 (3,000 ppm)



- R327 at 3,000 ppm shown to be highly effective against *E. coli* without affecting growing, healthy eukaryotic cells.
- R327 rapidly and irreversibly shuts down the ATP in *E. coli*, not allowing it to divide and grow.

R327 activity against *Staphylococcus aureus*

Without R327



R327 (2,300 ppm)



- R327 at 2,300 ppm shows to be highly effective against *S. aureus* without affecting growing, healthy eukaryotic cells.
- R327 rapidly and irreversibly shuts down the ATP in *S. aureus*, not allowing it to divide and grow.




R327 works to kill bacteria 'unlike any antibiotic ever seen' with multiple mechanisms of action. R327 is rapidly and irreversibly bactericidal against Gram-negative *E. coli* bacteria in both active and stationary phase cell with the potential to outperform the best in class commercial antibiotics.

- Italicise all *E. coli* and *S. aureus* words across the website

A Multi-Layered Mechanism of Action

R327 activity against *Escherichia coli*



- R327 at 3,000 ppm shown to be highly effective against *E. coli* without affecting growing, healthy eukaryotic cells.
- R327 rapidly and irreversibly shuts down the ATP in *E. coli*, not allowing it to divide and grow.

R327 activity against *Staphylococcus aureus*



- R327 at 2,300 ppm shows to be highly effective against *S. aureus* without affecting growing, healthy eukaryotic cells.
- R327 rapidly and irreversibly shuts down the ATP in *S. aureus*, not allowing it to divide and grow.

- If these four videos could be embedded into the page – please use this link to access the 4 video files <https://we.tl/t-xsjGkzLjf7>

Virus

RECCE® 529 is a new synthetic polymer formulation with indication against viruses. The Company looks forward to expanding upon this promising indication in due course. The Company continues to strengthen and expand their product pipeline in order to find a treatment for 'difficult to treat' viral infections.

- Add space between “course” and “The Company”

Manufacturing page

We have established a patented, automated, economical manufacturing process for our synthetic compounds. We have invested in a purpose built, wholly owned manufacturing facility, produced to the highest pharmaceutical standards

Furthermore, the manufacturing process is reproducible and has a CMC (Chemistry, Manufacturing, and Controls) data package, essential for clinical study materials.



- Full-stop missing

Sepsis page



Introducing R327 as the potential solution!

Early treatment with the correct antibiotic is key to improving patient outcome.

Helpful Sites



- Remove I from “Solution”

Burn Wound Infection Page

Overview

Aggressive infection is the leading cause of death and morbidity of burn wound sufferers. The most relevant and dangerous of burn wound infections are those involving Staphylococcus aureus (S. aureus), a Gram-positive bacteria located on the skin and mucous membranes (most often the nasal area).

S. aureus is the most dangerous of all of the many common staphylococcal bacteria. This bacteria often causes skin infections; however, it can also cause pneumonia, bone infections, meningitis and other invasive infections.

With the emergence of multi-drug resistant strains such as Methicillin-resistant Staphylococcus aureus (MRSA or ‘golden staph’), effective treatment options are often lacking. Patients with MRSA have significantly longer hospital stays and are estimated to be 64% more likely to die than people with a non-resistant form of the infection.

- Italicise staphylococcus aureus (s.aureus)

Events and presentations page

Resources

Fact Sheets & Posters

2023 Edison Group - Research Report

View PDF

2023 MST Access - Update Report

View PDF

2022 Fact Sheet (German) 2022

View PDF

2023 Fact Sheet

View PDF

2021 Recce Scientific Poster

View PDF

2022 Equity Research Report (December Update)

View PDF

Presentations

- Please ensure all these links are linked to the correct files – please check all files in all sections.

Top 20 shareholders page



All 2023 2022 2021

Archive

February 28, 2023

January 31, 2023



- Please add March & April (can gather files from live/existing website)

In the News page



Article

Proactive Investors - The smart money in medicine: the silent pandemic

Published 30 Mar 2023

Recce Pharmaceuticals is working on a solution.

Read Full Article

- Can these headlines also be linked to the full article? - Thanks